New hope for Tough-to-Treat blood cancer patients in major drug trial

NCT ID NCT04501120

Summary

This study is testing the safety and dosing of a new oral drug called lisaftoclax, both by itself and combined with other cancer drugs, for people with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The goal is to find the safest and most effective dose to control the disease. Researchers will also measure how the drug works in the body and if it helps patients live longer or without their cancer getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chongqing University Cancer Hospital

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

    Contact

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510080, China

    Contact

  • Henan Tumor Hospital

    RECRUITING

    Zhengzhou, Henan, China

    Contact

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

    Contact

  • Shanghai The Sixth People' s Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guandong, China

    Contact

  • The First affiliated hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

    Contact

  • Union Hospital medical college Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430022, China

    Contact

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610044, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xiangya Hospital Central South University

    RECRUITING

    Changsha, Hunan, China

    Contact

    Contact

  • Zhongnan Hospital of Hunan university

    RECRUITING

    Wuhan, Hubei, 430071, China

    Contact

    Contact

  • the First Affiliated Hospital, College of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.